Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival

Zarah Glad Zimling, Jens Benn Sørensen, Thomas Alexander Gerds, Cecilia Bech, Claus Bøgelund Andersen, Eric Santoni-Rugiu

Research output: Contribution to journalJournal articleResearchpeer-review

32 Citations (Scopus)

Abstract

The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.
Original languageEnglish
JournalJournal of Thoracic Oncology
Volume7
Issue number1
Pages (from-to)249-56
Number of pages8
ISSN1556-0864
DOIs
Publication statusPublished - 2012

Cite this